Publications
562
Citations
19,881
Est. group size
~15
Recurring co-author estimate
Active years
49
Publishing since 1978
Timothy L. Ratliff's research centers on urological cancers, particularly bladder and prostate cancer, with attention to immune system involvement, cancer cell metabolism (such as cholesterol processing), and mechanisms of drug resistance in prostate cancer treatment. Recent work has examined how epigenetic regulators (DNA methyltransferases, or DNMTs) contribute to resistance against the prostate cancer drug enzalutamide, as well as classification of precancerous lesions and models for studying aging alongside cancer.
Publication output was relatively steady at single digits to low teens per year from 2017-2022, then showed an unusual sharp spike in 2023 (152 publications, largely supplementary data files from one study) before returning to lower single-digit counts in subsequent years.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- International Society of Urological Pathology Consensus on Cancer Precursor Lesions. Working Group 1
The American Journal of Surgical Pathology · 2025
- Abstract 3085: Cholesterol sulfotransferase SULT2B1b suppresses prostate tumor growth and regulates cholesterol metabolism in prostate cancer cells
Cancer Research · 2024
- Challenges and opportunities for modeling aging and cancer
Cancer Cell · 2023
- Figure S2 from Targeting DNMTs to Overcome Enzalutamide Resistance in Prostate Cancer
2023
- Data from Targeting DNMTs to Overcome Enzalutamide Resistance in Prostate Cancer
2023
- Supplementary Data from Targeting DNMTs to Overcome Enzalutamide Resistance in Prostate Cancer
2023
- Supplementary Data from Targeting DNMTs to Overcome Enzalutamide Resistance in Prostate Cancer
2023
- Figure S2 from Targeting DNMTs to Overcome Enzalutamide Resistance in Prostate Cancer
2023
- Figure S7 from Targeting DNMTs to Overcome Enzalutamide Resistance in Prostate Cancer
2023
- Figure S3 from Targeting DNMTs to Overcome Enzalutamide Resistance in Prostate Cancer
2023
- Figure S7 from Targeting DNMTs to Overcome Enzalutamide Resistance in Prostate Cancer
2023
- Figure S3 from Targeting DNMTs to Overcome Enzalutamide Resistance in Prostate Cancer
2023
- Figure S5 from Targeting DNMTs to Overcome Enzalutamide Resistance in Prostate Cancer
2023
- Figure S6 from Targeting DNMTs to Overcome Enzalutamide Resistance in Prostate Cancer
2023
- Data from Targeting DNMTs to Overcome Enzalutamide Resistance in Prostate Cancer
2023
- Cancer Research×8
- bioRxiv (Cold Spring Harbor Laboratory)×5
- Frontiers in Immunology×4
- Molecular Cancer Research×3
- PMC×3
- Michael Gong
Medicine · The Ohio State University
- Debasish Sundi
Medicine · The Ohio State University
- Ahmad Shabsigh
Medicine · The Ohio State University
- Michael O. Koch
Medicine · Indiana University
- Debra L. Zynger
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 20, 2026.
Claim or correct this profile